| Desiree R Washington, LICSW, LCSW-C | |
|
13206 Idlewild Dr, Bowie, MD 20715-1406 | |
| (216) 965-4495 | |
| (240) 245-4663 |
| Full Name | Desiree R Washington |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 13206 Idlewild Dr, Bowie, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881154326 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | LC50078373 (District Of Columbia) | Secondary |
| 1041C0700X | Social Worker - Clinical | 13593 (Maryland) | Primary |
| Entity Name | Desired Social Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902366453 PECOS PAC ID: 5597007617 Enrollment ID: O20190422000072 |
News Archive
Recently a team of researchers from Saudi Arabia, the United Arab Emirates, and the United States assessed travel-related anxiety in healthcare workers (HCWs) considering the emergence of new variants caused by SARS-CoV-2 mutations.
The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
A team of investigators at The Cancer Institute of New Jersey (CINJ); Rutgers, The State University of New Jersey; and Princeton University, have determined that cancer cells are "addicted" to a self-preservation process known as autophagy. They also showed that the inhibition of that process could prove to be a valuable treatment approach for aggressive cancers. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer. But nearly 80 percent of patients who receive ADT report experiencing hot flashes during and after treatment. Moffitt Cancer Center researchers are working to determine what genetic factors and other characteristics might make prostate cancer patients more likely to experience hot flashes during and after therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Desiree R Washington, LICSW, LCSW-C 13206 Idlewild Dr, Bowie, MD 20715-1406 Ph: (216) 965-4495 | Desiree R Washington, LICSW, LCSW-C 13206 Idlewild Dr, Bowie, MD 20715-1406 Ph: (216) 965-4495 |
News Archive
Recently a team of researchers from Saudi Arabia, the United Arab Emirates, and the United States assessed travel-related anxiety in healthcare workers (HCWs) considering the emergence of new variants caused by SARS-CoV-2 mutations.
The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
A team of investigators at The Cancer Institute of New Jersey (CINJ); Rutgers, The State University of New Jersey; and Princeton University, have determined that cancer cells are "addicted" to a self-preservation process known as autophagy. They also showed that the inhibition of that process could prove to be a valuable treatment approach for aggressive cancers. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer. But nearly 80 percent of patients who receive ADT report experiencing hot flashes during and after treatment. Moffitt Cancer Center researchers are working to determine what genetic factors and other characteristics might make prostate cancer patients more likely to experience hot flashes during and after therapy.
› Verified 4 days ago
Mr. Michael King Jr., LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 612 Stillwater Pl, Bowie, MD 20721 Phone: 240-893-3739 | |
Nicole S Wright, MSW, LICSW, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12210 Maycheck Ln, Bowie, MD 20715 Phone: 202-236-3160 | |
Alyssa Robin Krieger, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12021 Quarum Pl, Bowie, MD 20720 Phone: 240-486-6077 | |
Catherine Robinson, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 15480 Annapolis Rd, Bowie, MD 20715 Phone: 240-353-3492 | |
Evelin A Perry, MSW, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 16701 Melford Blvd Ste 400, Bowie, MD 20715 Phone: 415-424-4266 Fax: 415-520-6633 | |
Ms. Rianna Berkeley, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10236 Lake Arbor Way, Bowie, MD 20721 Phone: 240-681-9653 | |
Tameka Thompson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 15480 Annapolis Rd Ste 202-148, Bowie, MD 20715 Phone: 240-350-8597 |